

2023 Company Review

Dear LinusBio friends,

It is my pleasure to share this year-end update. 2023 has passed so quickly and what an extraordinary year it has been for LinusBio. We've settled into our new cutting-edge lab in NJ, welcomed new faces to our growing team, defied market trends with strategic investments, and fostered key partnerships – all gearing up for the excitement that awaits us in 2024.

Here's a brief rundown of LinusBio's 2023 achievements and a glimpse of what's next on the horizon.

Thriving Partnerships and Strategic Investments

Our Series A2 funding round has significantly boosted our trajectory, with [Y.A.C. Holdings leading the latest investment](#), resulting in a remarkable 30% increase in LinusBio's valuation. This partnership not only solidifies our financial standing but also opens doors for collaborative innovations in hardware development and lab upscaling.

Growing Stronger Together

The LinusBio family has expanded to over 20 dedicated members and counting! Our team, a diverse blend of talent and expertise, continues to be the driving force behind our success. Each addition contributes to the collaborative spirit and innovative thinking that defines LinusBio.



The LinusBio team

Consistent Revenue Growth

We're pleased to share that our dedication to precision exposome medicine has resulted in more than doubling our revenue. This growth underscores the growing acknowledgment and demand for our innovative approach, seamlessly connecting exposomics and human health.

Pioneering Statewide Impact

LinusBio is in the process of finalizing an agreement to become a state-wide testing lab for a U.S. state. We are excited about the significant impact this partnership will have on advancing health outcomes at a broader scale - stay tuned for more details coming very soon.

Global Recognition and Interest

LinusBio's influence extends beyond borders, with substantial interest emanating from Japan and the Middle East. The global recognition of our work underscores the universal importance of precision medicine in shaping the future of healthcare.

New Horizons in Pharma Collaborations

LinusBio continues to expand its pharma collaborations and we hope to make a major announcement in Q1 2024. As we embark on new pharmaceutical partnerships. These collaborations promise to further enhance our capabilities, bringing us closer to achieving our vision of identifying complex conditions early and improving treatment outcomes.

Introducing ClearStrand™ASD: A Breakthrough Autism Test

We're thrilled to announce that LinusBio is gearing up to launch its inaugural product, ClearStrand™ASD, in Q1 of 2024. This innovative test is designed to assist healthcare providers (HCPs) in diagnosing autism spectrum disorder (ASD) for children aged 1 month to 7 years, when autism is a concern.

ClearStrand™ASD, a high-complexity Laboratory Developed Test (LDT), will be conducted by a CLIA-certified laboratory and requires an order from a licensed healthcare provider. Stay tuned for more details on how ClearStrand™ASD is set to redefine early diagnostics and support for ASD concerns.



As we enter 2024, we are filled with gratitude for the strides we've taken and the challenges we've overcome together. LinusBio remains steadfast in its commitment to advancing precision medicine breakthroughs and improving lives. Thank you for being an integral part of our journey.

Wishing you a joyful holiday season and a prosperous New Year!

Dr. Manish Arora, Co-Founder and CEO